Biomarin Pharmaceutical Inc
Research Biomarin Pharmaceutical Inc (BMRN) on Bullrun: market cap USD 12.80B, P/E 178.3. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerBMRN
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 12.80B
- P/E178.3
- Financial periodQ2 2026
- RevenueUSD 989.71M
- Net incomeUSD 44.76M
- Free cash flowUSD 133.86M
- Gross margin79.5%
Valuation Snapshot
latest market cap is USD 12.80B; P/E is 178.3.
Peer valuation comparison
Latest P/E is 178.27x versus a Healthcare sector median of 24.46x (628.8% above).
Latest P/E is 178.27x versus a United States median of 24.87x (616.9% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 3.22B | USD 348.90M | USD 724.96M | 77.7% | 1.8 | USD 1.31B | USD 597.18M | USD 6.09B |
| FY2024 | USD 2.85B | USD 426.90M | USD 487.42M | 79.7% | 2.21 | USD 942.84M | USD 602.71M | USD 5.66B |
| FY2023 | USD 2.42B | USD 167.60M | USD 62.57M | 78.0% | 0.87 | USD 755.13M | USD 1.10B | USD 4.95B |
| FY2022 | USD 2.10B | USD 141.60M | USD 54.94M | 76.0% | 0.75 | USD 724.53M | USD 1.08B | USD 4.60B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 12.80B | 178.3 | n/a | n/a |
| 2025 | 2025-12-31 | USD 11.43B | 33.4 | n/a | n/a |
| 2024 | 2024-12-31 | USD 12.54B | 29.9 | n/a | n/a |
| 2023 | 2023-12-29 | USD 18.16B | 126.9 | n/a | n/a |
| 2022 | 2022-12-30 | USD 19.23B | 246.4 | n/a | n/a |
| 2021 | 2021-12-31 | USD 16.25B | n/a | n/a | n/a |
About Biomarin Pharmaceutical Inc
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Biomarin Pharmaceutical Inc's market cap?
Biomarin Pharmaceutical Inc's market capitalization is USD 12.80B.
What is Biomarin Pharmaceutical Inc's P/E ratio?
Biomarin Pharmaceutical Inc's price-to-earnings (P/E) ratio is 178.3.
What does Biomarin Pharmaceutical Inc do?
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally.